AGLE logo

Aeglea BioTherapeutics (AGLE) Free Cash Flow

Annual FCF

-$80.18 M
-$25.89 M-47.69%

December 31, 2022

Summary

Performance

1-Year Change

-47.69%

3-Year Change

-19.35%

5-Year Change

-217.75%

15-Year Change

-217.75%

AGLE Free Cash Flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$7.52 M

3-Year Low

-$80.18 M
AGLE annual free cash flow is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
AGLE previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
AGLE next annual earnings announcement has not yet been scheduled

OtherAGLEcash flowmetrics:

Annual CFO

-$80.14 M
AGLE annual cash flow from operations is -$80.14 million

Annual CFF

$42.68 M
AGLE annual cash flow from financing activities is $42.68 million

Annual CFI

$57.01 M
AGLE annual cash flow from investing activities is $57.01 million

Annual CAPEX

$38.00 K
AGLE annual capital expenditures is $38.00 thousand

Quarterly FCF

-$34.60 M
-$17.95 M-107.88%

September 30, 2023

Summary

Performance

3-Month Change

-107.88%

1-Year Change

-129.59%

3-Year Change

-91.12%

5-Year Change

-302.15%

AGLE Quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$2.05 M
AGLE quarterly free cash flow is currently -1786.01% below its historical high of $2.05 million

3-Year Low

-$34.60 M
AGLE quarterly free cash flow is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
AGLE previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
AGLE next earnings announcement has not yet been scheduled

OtherAGLEcash flowmetrics:

Quarterly CFO

-$34.60 M
AGLE quarterly cash flow from operations is -$34.60 million

Quarterly CFF

-$12.53 M
AGLE quarterly cash flow from financing activities is -$12.53 million

Quarterly CFI

-$97.63 M
AGLE quarterly cash flow from investing activities is -$97.63 million

Quarterly CAPEX

-
AGLE quarterly capital expenditures value is unknown

TTM FCF

-$87.01 M
-$19.53 M-28.94%

September 30, 2023

Summary

Performance

3-Month Change

-28.94%

1-Year Change

-7.02%

3-Year Change

-9.6%

5-Year Change

-29.52%

AGLE TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$1.36 M

3-Year Low

-$87.01 M
AGLE TTM free cash flow is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
AGLE previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
AGLE next earnings announcement has not yet been scheduled

OtherAGLEcash flowmetrics:

TTM CFO

-$87.01 M
AGLE TTM cash flow from operations is -$87.01 million

TTM CFF

$197.46 M
AGLE TTM cash flow from financing activities is $197.46 million

TTM CFI

-$59.12 M
AGLE TTM cash flow from investing activities is -$59.12 million

TTM CAPEX

-
AGLE TTM capital expenditures value is unknown

Free Cash Flow Formula

FCF = Cash From Operations − CAPEX

Annual FCF

-$80.18 M
AGLE annual free cash flow is -$80.18 million

Annual CFO

-$80.14 M
AGLE annual cash flow from operations is -$80.14 million

Annual CAPEX

$38.00 K
AGLE annual capital expenditures is $38.00 thousand

AGLE Free Cash Flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-47.7%-129.6%-7.0%
3 y3 years-19.4%-91.1%-9.6%
5 y5 years-217.8%-302.1%-29.5%

AGLE Free Cash Flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year+47.7%at low+129.6%at low+60.3%at low
5 y5-year+47.7%at low-1786.0%at low+63.7%at low
alltimeall time+966.8%at low-1786.0%at low+6307.5%at low

Aeglea BioTherapeutics Free Cash Flow History

DateAnnualQuarterlyTTM
Sep 2023
-
-$34.60 M(+107.9%)
-$87.01 M(+28.9%)
Jun 2023
-
-$16.64 M(-5.6%)
-$67.49 M(-5.6%)
Mar 2023
-
-$17.63 M(-2.8%)
-$71.52 M(-10.8%)
Dec 2022
-$80.18 M(+47.7%)
-$18.14 M(+20.4%)
-$80.18 M(-1.4%)
Sep 2022
-
-$15.07 M(-27.1%)
-$81.31 M(-2.4%)
Jun 2022
-
-$20.67 M(-21.4%)
-$83.33 M(+37.5%)
Mar 2022
-
-$26.30 M(+36.5%)
-$60.61 M(+11.6%)
Dec 2021
-$54.29 M(-32.2%)
-$19.27 M(+12.7%)
-$54.29 M(+2.1%)
Sep 2021
-
-$17.09 M(-933.0%)
-$53.15 M(-1.9%)
Jun 2021
-
$2.05 M(-110.3%)
-$54.16 M(-29.6%)
Mar 2021
-
-$19.98 M(+10.2%)
-$76.95 M(-3.9%)
Dec 2020
-$80.06 M(+19.2%)
-$18.13 M(+0.2%)
-$80.06 M(+0.8%)
Sep 2020
-
-$18.10 M(-12.7%)
-$79.39 M(+1.0%)
Jun 2020
-
-$20.74 M(-10.2%)
-$78.64 M(+5.8%)
Mar 2020
-
-$23.08 M(+32.1%)
-$74.34 M(+10.7%)
Dec 2019
-$67.18 M(+106.0%)
-$17.47 M(+0.7%)
-$67.18 M(+17.6%)
Sep 2019
-
-$17.35 M(+5.5%)
-$57.12 M(+18.1%)
Jun 2019
-
-$16.44 M(+3.2%)
-$48.37 M(+17.9%)
Mar 2019
-
-$15.93 M(+115.1%)
-$41.01 M(+25.7%)
DateAnnualQuarterlyTTM
Dec 2018
-$32.62 M(+29.3%)
-$7.40 M(-13.9%)
-$32.62 M(+4.3%)
Sep 2018
-
-$8.60 M(-5.2%)
-$31.28 M(+3.7%)
Jun 2018
-
-$9.08 M(+20.6%)
-$30.15 M(+11.4%)
Mar 2018
-
-$7.53 M(+24.2%)
-$27.06 M(+7.2%)
Dec 2017
-$25.23 M(+32.4%)
-$6.06 M(-18.9%)
-$25.23 M(+6.7%)
Sep 2017
-
-$7.48 M(+24.9%)
-$23.65 M(+7.3%)
Jun 2017
-
-$5.99 M(+5.0%)
-$22.03 M(+6.1%)
Mar 2017
-
-$5.70 M(+27.4%)
-$20.77 M(+9.0%)
Dec 2016
-$19.05 M(+70.3%)
-$4.48 M(-23.7%)
-$19.05 M(+23.3%)
Sep 2016
-
-$5.87 M(+24.2%)
-$15.45 M(+14.2%)
Jun 2016
-
-$4.72 M(+18.3%)
-$13.53 M(+6.6%)
Mar 2016
-
-$3.99 M(+357.0%)
-$12.69 M(+13.4%)
Dec 2015
-$11.19 M(+48.9%)
-$873.00 K(-77.9%)
-$11.19 M(-16.4%)
Sep 2015
-
-$3.94 M(+1.7%)
-$13.38 M(+18.3%)
Jun 2015
-
-$3.88 M(+55.6%)
-$11.31 M(+30.8%)
Mar 2015
-
-$2.49 M(-18.7%)
-$8.65 M(+15.1%)
Dec 2014
-$7.52 M
-$3.07 M(+63.5%)
-$7.52 M(+68.9%)
Sep 2014
-
-$1.88 M(+54.1%)
-$4.45 M(+72.8%)
Jun 2014
-
-$1.22 M(-10.4%)
-$2.58 M(+89.6%)
Mar 2014
-
-$1.36 M
-$1.36 M

FAQ

  • What is Aeglea BioTherapeutics annual free cash flow?
  • What is the all time high annual FCF for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics annual FCF year-on-year change?
  • What is Aeglea BioTherapeutics quarterly free cash flow?
  • What is the all time high quarterly FCF for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics quarterly FCF year-on-year change?
  • What is Aeglea BioTherapeutics TTM free cash flow?
  • What is the all time high TTM FCF for Aeglea BioTherapeutics?
  • What is Aeglea BioTherapeutics TTM FCF year-on-year change?

What is Aeglea BioTherapeutics annual free cash flow?

The current annual FCF of AGLE is -$80.18 M

What is the all time high annual FCF for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high annual free cash flow is -$7.52 M

What is Aeglea BioTherapeutics annual FCF year-on-year change?

Over the past year, AGLE annual free cash flow has changed by -$25.89 M (-47.69%)

What is Aeglea BioTherapeutics quarterly free cash flow?

The current quarterly FCF of AGLE is -$34.60 M

What is the all time high quarterly FCF for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high quarterly free cash flow is $2.05 M

What is Aeglea BioTherapeutics quarterly FCF year-on-year change?

Over the past year, AGLE quarterly free cash flow has changed by -$19.53 M (-129.59%)

What is Aeglea BioTherapeutics TTM free cash flow?

The current TTM FCF of AGLE is -$87.01 M

What is the all time high TTM FCF for Aeglea BioTherapeutics?

Aeglea BioTherapeutics all-time high TTM free cash flow is -$1.36 M

What is Aeglea BioTherapeutics TTM FCF year-on-year change?

Over the past year, AGLE TTM free cash flow has changed by -$5.70 M (-7.02%)